Abstract
Postmarketing drug surveillance refers to the monitoring of drugs once they reach the market after clinical trials. It evaluates drugs taken by individuals under a wide range of circumstances over an extended period of time. Such surveillance is much more likely to detect previously unrecognized positive or negative effects that may be associated with a drug. The majority of postmarketing surveillance concern adverse drug reactions (ADRs) monitoring and evaluation. Other important postmarketing surveillance components include unapproved or off-label drug use, problems with orphan drugs, and lack of paediatric formulations, as well as issues concerning international clinical trials in paediatric population. The process of evaluating and improving the safety of medicines used in paediatric practice is referred to as paediatric pharmacovigilance. It requires special attention. Childhood diseases and disorders may be qualitatively and quantitatively different from their adult equivalents. This may affect either benefit or risk of therapies (or both), with a resulting impact on the risk/benefit balance. In addition, chronic conditions may require chronic treatment and susceptibility to ADRs may change throughout the patient’s lifetime according to age and stage of growth and development. Therefore, paediatric pharmacovigillance aspects need to be tailored to a number of variables based on heterogeneity of paediatric population. This chapter will summarize and discuss the key issues.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
Bate A, Lindquist M, Edwards IR (1998) A Bayesian neural network method for adverse drug reaction signal generation. Eur J Clin Pharmacol 54:315–321
Bücheler R, Schwab M, Mörike K et al (2002) Off label prescribing to children in primary care in Germany: retrospective cohort study. BMJ 324:1311–1312
Chalumeau M, Treluyer J, Salanave B et al (2000) Off label and unlicensed drug use among French office based paediatricians. Arch Dis Child 83:502–505
Choonara I (2006) Paediatric pharmacovigilance. Paed Perinat Drug Ther 7:50–53
Cirko-Begovic A, Vrhovac B, Bakran I (1989) Intense monitoring of adverse drug reactions in infants and preschool children. Eur J Clin Pharmacol 36:63–65
Clark RH, Bloom BT, Spitzer AR et al (2006) Reported medication use in the neonatal intensive care unit: data from a large national data set. Paediatrics 117(6):1979–1987
Conroy S, Choonara I, Impicciatore P et al (2000) Survey on unlicensed and off label drug use in paediatric wards in European countries. BMJ 320:79–82
European Medicines Agency. Guideline on the need for non-clinical testing in juvenile animals of pharmaceuticals for paediatric indication (EMEA/CHMP/SWP/169215/2005), published 24.01.2008
European Medicines Agency. Medicines for children. http://www.ema.europa.eu/pdfs/human/comp/29007207en.pdf. Accessed 27 Jan 27 2010
Evans SJW (2008) Stratification for spontaneous report databases. Drug Saf 31(11):1049–1053
Evans SJW, Waller PC, Davis S (2001) Use of proportional reporting ratios (PRRs) for signal generation from spontaneous adverse drug reaction reports. Pharmacoepidemiol Drug Saf 10(6):483–486
Fortescue EB, Kaushal R, Landrigan CP et al (2003) Prioritizing strategies for preventing medication errors and adverse drug events in paediatric inpatients. Paediatrics 111:722–729
Garcia Rodriguez LA, Perez Gutthann S (1998) Use of the UK general practice research database for pharmacoepidemiology. Br J Clin Pharmacol 45:419–425
Gijsen R, Jochemsen H, vanDijk L et al (2009) Frequency of ill-founded off-label prescribing in Dutch general practice. Pharmacoepidemiol Drug Saf 18:84–91
Grégoire MC, Finley A (2007) Why were we abandoned? Orphan drugs in paediatric pain. Paediatr Child Health 12(2):95–96
Haffner ME (2006) Adopting orphan drugs – two dozen years of treating rare diseases. N Engl J Med 354:445–447
Haffner S, von Laue N, Wirth S et al (2005) Detecting adverse drug reactions on paediatric wards: intensified surveillance versus computerised screening of laboratory values. Drug Saf 28(5):453–464
Hartford CG, Petchel KS, Mickail H et al (2006) Pharmacovigilance during the pre-approval phases: an evolving pharmaceutical industry model in response to ICH E2E, CIOMS VI, FDA and EMEA/CHMP risk-management guidelines. Drug Saf 29(8):657–673
Horen B, Montastruc JL, Lapeyre-Mestre M (2002) Adverse drug reactions and off-label drug use in paediatric outpatients. Br J Clin Pharmacol 54:665–670
Impicciatore P, Choonara I, Clarkson A et al (2001) Incidence of adverse drug reactions in paediatric in/out-patients: a systemic review and meta-analysis of prospective studies. Br J Clin Pharmacol 52:77–83
International Conference on Harmonisation (ICH) (2000) Topic E 11: clinical investigation of medicinal products in the paediatric population. http://www.europa.emea.eu./pdfs/human/ich/271199EN.pdf
Johann-Liang R, Wyeth J, Chen M et al (2009) Paediatric drug surveillance and the food and drug administration’s adverse event reporting system: an overview of reports, 2003–2007. Pharmacoepidemiol Drug Saf 18:24–27
Kaushal R, Bates DW, Landrigan C et al (2001) Medication errors and adverse drug events in paediatric inpatients. JAMA 285:2114–2120
Kearns GL, Abdel-Rahman SM, Alander SW et al (2003) Developmental pharmacology–drug disposition, action, and therapy in infants and children. N Engl J Med 349(12):1157–1167
Kimland E, Rane A, Ufer M et al (2005) Paediatric adverse drug reactions reported in Sweden from 1987 to 2001. Pharmacoepidemiol Drug Saf 14:493–499
Kimland E, Bergman U, Lindemalm S et al (2007) Drug related problems and off-label drug treatment in children a seen at a drug information centre. Eur J Pediatr 166:527–532
McIntyre J, Conroy S, Avery A et al (2000) Unlicensed and off-label prescribing of drugs in general practice. Arch Dis Child 83:498–501
Meyboom RH, Egberts AC, Edwards IR et al (1997) Principles of signal detection in pharmacovigilance. Drug Saf 16(6):355–365
Mühlbauer B, Janhsen K, Pichler J et al (2009) Off-label use of prescription drugs in childhood and adolescence. Dtsch Arztebl Int 106(3):25–31
Neubert A, Dormann H, Weiss J et al (2006) Are computerised monitoring systems of value to improve pharmacovigilance in paediatric patients? Eur J Clin Pharmacol 62(11):959–965
Nunn T, Williams J (2005) Formulation of medicines for children. Br J Clin Pharmacol 59(6):674–676
O’Donnell CP, Stone RJ, Morley CJ (2002) Unlicensed and off-label drug use in an Australian intensive care unit. Paediatrics 110:e52
Pandolfini C, Binati M (2005) A literature review on off-label drug use in children. Eur J Pediatr 164:552–558
Roberts R, Rodriguez W, Murphy D et al (2003) Paediatric drug labeling. Improving the safety and efficacy of pediatrc therapies. JAMA 290(7):905–911
Sanz E, Boada J (1987) Adverse drug reactions in paediatric outpatients. Int J Clin Pharmacol Res 7:169–172
‘tJong GW, Eland IA, Strukenboom MC et al (2002) Unlicenced and off-label prescription of drugs to children: population based cohort study. BMJ 324:1313–1314
Turner S, Nunn AJ, Fielding K et al (1999) Adverse drug reactions to unlicensed and off label drugs on paediatric wards: a prospective study. Acta Paediatr 88(9):965–968
Ufer M, Kimland E, Bergman U (2004) Adverse drug reactions and off-label prescribing for paediatric outpatients: a one-year survey of spontaneous reports in Sweden. Pharmacoepidemiol Drug Saf 13:47–152
Wong I, Murray ML (2005) The potential of UK clinical databases in enhancing paediatric medication research. Br J Clin Pharmacol 59(6):750–755
World Health Organization Guideline (2007) Promoting safety of medicines for children. www.who.int/medicines/publications/essentialmedicines/Promotion_safe_med_childrens.pdf
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2011 Springer-Verlag Berlin Heidelberg
About this chapter
Cite this chapter
Vlahović-Palčevski, V., Mentzer, D. (2011). Postmarketing Surveillance. In: Seyberth, H., Rane, A., Schwab, M. (eds) Pediatric Clinical Pharmacology. Handbook of Experimental Pharmacology, vol 205. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-642-20195-0_17
Download citation
DOI: https://doi.org/10.1007/978-3-642-20195-0_17
Published:
Publisher Name: Springer, Berlin, Heidelberg
Print ISBN: 978-3-642-20194-3
Online ISBN: 978-3-642-20195-0
eBook Packages: Biomedical and Life SciencesBiomedical and Life Sciences (R0)